Inhibitor of DNA binding 2 (Id2) is a negative regulator of basic helix-loop-helix transcription factors and is involved in the control of cellular differentiation and proliferation. By using a twostep chemical carcinogenesis protocol, we evaluated the role of Id2 in skin tumor formation in mice. Twenty weeks after the initiation, the number of tumors formed in the Id2 2/2 mice was 3.5-fold higher than that in their wild-type littermates, whereas the diameter of tumors in the Id2 2/2 mice was about half of that of the tumors in the wild-type mice. In the Id2 2/2 mice, epidermal gd T cells, which play a key role in immunosurveillance against skin tumor development, were barely detectable. Although histological analyses demonstrated no apparent difference in tumor cell type, tumor vessel formation or apoptosis, the proportion of proliferating cells was reduced in the tumors in the Id2 2/2 mice compared with those in the wild-type mice. In the wild-type mice, the expression of Id2 was enhanced in skin tumors compared with that in ear epidermal cells. Biochemical analysis demonstrated that cyclin D1 was reduced at the protein level in the tumors in the Id2 2/2 mice, whereas other factors such as cyclin E and p27 were not altered significantly. Our results reveal that Id2 plays a dual role in skin tumorigenesis by suppressing tumor development through the establishment of epidermal gd T cell-mediated skin immunosurveillance and by promoting tumor cell proliferation via the control of the cyclin D1 protein level.
Introduction
In addition to transcription factors themselves, functional regulators of transcription factors are deeply involved in coordinating the execution of many biological processes including cellular differentiation and proliferation. The four inhibitors of DNA binding (Id), Id1-Id4, are typical examples of such factors in mammals. They are structurally characterized by a highly conserved helix-loop-helix (HLH) motif and by a lack of a DNA-binding domain. These Id proteins negatively regulate the function of basic HLH transcription factors such as MyoD and E proteins through the interactions between HLH domains (1) (2) (3) (4) . Various in vitro and in vivo studies have demonstrated the involvement of Id proteins in the modulation of cell differentiation and in the stimulation of cell proliferation, as reviewed elsewhere (2) (3) (4) .
Id proteins control cell proliferation by suppressing the gene expression of cyclin-dependent kinase (CDK) inhibitors such as p15, p16 and p21 (2-4). These genes are induced by basic HLH factors through E-boxes present in their promoter regions. Id proteins have also been reported to regulate cell proliferation by interacting with non-basic HLH factors such as Ets proteins and pocket proteins including the retinoblastoma protein (2) (3) (4) . Accumulating evidence has shown that the enhanced expression of Id proteins and/or genes is observed in a wide range of human tumors, including squamous cell carcinomas in the skin (5) and that their elevated expression levels are correlated with high grade malignancies and poor prognosis (3, 4) . These observations suggest that Id proteins are involved in tumorigenesis as intrinsic tumor cell factors.
Id proteins also play a role in regulating tumor development as environmental factors. Tumor cells xenografted onto mutant mice with a reduced dosage of Id1 and/or Id3 fail to form a tumor mass due to impaired angiogenesis, although the effect depends on the tumor type (6) . A recent report has demonstrated that the suppression of p21 expression by Id1 is required for the generation of the bone marrow-derived endothelial progenitor cells that are recruited to the site of angiogenesis (7) . On the other hand, Id1-deficient mice are susceptible to de novo skin tumor formation by two-step chemical carcinogenesis. This is due to a reduced number of epidermal cd T cells (8) , which play a crucial role in immune surveillance against skin tumors (9) . These findings suggest that Id proteins also engage in tumorigenesis as a host factor, negatively or positively.
By using a two-step chemical carcinogenesis protocol involving dimethylbenz(a)anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA) (10), we examined whether inhibitor of DNA binding 2 (Id2) is involved in skin tumor formation and found that Id2 À/À mice display a susceptibility to skin tumor formation, probably due to their markedly reduced number of epidermal cd T cells. Furthermore, the absence of Id2 results in impaired proliferation of tumor cells in association with decreased cyclin D1 expression at the protein level. Our work thus demonstrates the contradictory functions of Id2 in skin tumorigenesis, acting not only as a factor intrinsic to tumor cells but also as an environmental factor.
Materials and methods

Mice and chemical carcinogenesis We established Id2
À/À mice (11) and used the F1 mice of crosses between 129/ Sv and C57Bl/6 mouse strains, together with their wild-type littermates as controls. All experimental procedures followed the guidelines of the University of Fukui for animal experiments. Two-step chemical carcinogenesis was performed as described previously (9) . In brief, the dorsal skin was initiated with a single dose of DMBA (50 lg in 10 ll acetone) on the day of birth, and one week after the initiation, the mice had their back shaved and were subsequently treated twice a week with TPA (5 lg in 50 ll acetone) for 20 weeks.
Histological analysis and immunohistochemistry
The tumors and skin samples were fixed with 4% paraformaldehyde in phosphate-buffered saline overnight, embedded in paraffin, processed using a standard protocol and cut into thin sections (5 lm). For the immunohistochemistry, the sections were microwaved in 10 mM citrate buffer (pH 6.0) for target retrieval, blocked with 0.3% H 2 O 2 solution for 5 min and with serum for 1 h and then reacted with primary antibodies against keratin 6 (Lab Vision, Fremont, CA, MS-766), keratin 10 (Chemicon, Temecula, CA, MAB3230), keratin 14 (Chemicon, MAB3232), Ki-67 (DAKO, Carpinteria, CA, M7249) or von Willebrand factor (DAKO, A0082) for 1 h. The visualization was performed with a DAKO EnVisionþSystem kit (DAKO). For immunofluorescence staining, the sections were reacted with the secondary antibody against mouse IgG-Alexa Fluor 594 (Molecular Probes, Eugene, OR). For the terminal deoxynucleotidyltransferase-mediated deoxyuridine triphosphate end-labeling assay, the tissue sections were treated with 20 lg/ml of proteinase K and incubated with a terminal deoxynucleotidyltransferase-mediated deoxyuridine triphosphate end-labeling reaction mixture (Roche Applied Science, Indianapolis, IN) for 1 h at 37°C. In both procedures, counterstaining was performed with Mayer's hematoxylin.
Real-time reverse transcription-polymerase chain reaction Total RNA was prepared from tissues with an RNeasy Mini Kit (QIAGEN, Valencia, CA). Complementary DNA was synthesized using the SuperScript II TM First Strand Synthesis System (Life Technologies, Carlsbad, CA) with random primers. Quantitative real-time reverse transcription-polymerase chain reaction was performed with the respective primer sets using SYBR Green PCR Master Mix (TaKaRa, Otsu, Japan) and was run on the ABI PRISM 7000 sequence detection system (PE Applied Biosystem, Foster City, CA). The data were normalized relative to b-actin amplification. The sequences of the primers used are as follows: Id1, 5#-GGAGCTGAACTCGGAGTCTGAA-3# (forward) and 5#-GATCGTCGGCTGGAACACA-3# (reverse); Id2, 5#-ACTCGCATCCCAC-TATCGTCAG-3# (forward) and 5#-TGCTATCATTCGACATAAGCTCAGA-3# (reverse); Id3, 5#-GGAAATCCTGCAGCGTGTCATA (forward) and 5#-GAGAT-CACAAGTTCCGGAGTGAG-3# (reverse); Id4, 5#-CTGTTTGGCCAGGCTGT-TGA-3# (forward) and 5#-CAATCATGCAAGACCAGTACCAGAG-3# (reverse); Cyclin D1, 5#-TCCCTAGCAAGCTGCCAAAC-3# (forward) and 5#-TGGACC-CACCACCAGTCTATG (reverse) and b-actin, 5#-TGACAGGATGCAGAAGGA-GA-3# (forward) and 5#-GCTGGAAGGTGGACAGTGAG-3# (reverse).
Western blot analysis
The tumors were homogenized in lysis buffer containing 25 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM ethylenediaminetetraacetic acid, 10% glycerol, 1 mM dithiothreitol and protease inhibitor mixture (Roche Applied Science) and were incubated for 30 min at 4°C. The supernatant obtained by centrifugation at 17 000g at 4°C for 20 min was used as the total tissue extract. Twenty micrograms of total proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride filter (ATTO, Tokyo, Japan). The primary antibodies used were as follows: cyclin D1 (Santa Cruz Biotechnology, Santa Cruz, CA, sc-6281), cyclin E (Santa Cruz Biotechnology, sc-25303), CDK2 (Santa Cruz Biotechnology, sc-163), CDK4 (Santa Cruz Biotechnology, sc-260), p16 (Santa Cruz Biotechnology, sc-1207), p21 (Pharmingen, Palo Alto, CA, 556431), p27 (Pharmingen, 610241), Id2 (Santa Cruz Biotechnology, sc-489), c-Fos (Santa Cruz Biotechnology, sc-52), c-Myc (Santa Cruz Biotechnology, sc-40), phospho-extracellular signal-regulated kinase (Erk) 1/2 (Santa Cruz Biotechnology, sc-81492) and b-actin (Sigma-Aldrich, St. Louis, MO, AC-15). The corresponding secondary antibodies conjugated with horse radish peroxidase anti-rabbit IgG (Biosource, Camarillo, CA, ALI3404) or antimouse IgG (Zymed Laboratories, South San Francisco, CA, 62-6520) were used. Immunoreactive bands were visualized using the enhanced chemiluminescence system (GE Healthcare, Piscataway, NJ) and were detected using the LAS-3000 imaging system (FUJIFILM, Tokyo, Japan).
Whole mount immunohistochemistry and flow cytometric analysis
Immunohistochemical analysis of epidermal sheets and flow cytometric analysis of ear auricle epidermal cells were performed as described (12, 13) . The antibodies used were fluorescein isothiocyanate-conjugated anti-MHC class II (American Type Culture Collection, TIB120) and PE-conjugated anti-CD3 (eBioscience, San Diego, CA, 2C11) antibodies. For the flow cytometry, fluorescein isothiocyanate-conjugated anti-Vc3 T cell receptor (Pharmingen, 536) and PE-conjugated anti-I-A d /I-E d (MHC class II) (Pharmingen, 2G9) antibodies were used.
Results
Id2 À/À mice are sensitive to chemical carcinogenesis but formed tumors are smaller in size than those of wild-type mice Id2 À/À mice and their wild-type littermates (wild-type, n 5 20 and Id2 À/À , n 5 16) were subjected to classical two-step chemical carcinogenesis (10) and induced to form de novo skin tumors. In both genotypes, tumors started to be detectable 6 weeks after the initiation (94% in Id2 À/À mice and 80% in their wild-type littermates), and all mice had developed skin tumors at 8 weeks. Twenty weeks after the initiation, the wild-type and Id2 À/À mice had developed 1.6 ± 0.6 and 5.6 ± 1.5 tumors per mouse, respectively, showing that 3.5-fold more tumors were formed in the Id2 À/À mice than in the control mice ( Figure 1A ). On the other hand, the mean tumor diameters at this time were 6.5 ± 1.8 mm in the wild-type mice and 3.1 ± 0.7 mm in the Id2 À/À mice, demonstrating that the mean diameter of the tumors in the Id2 À/À mice was 52% smaller than that in their wild-type littermates ( Figure 1B) . The histopathological analysis with hematoxylin and eosin-stained sections indicated that the tumors were exophytic papillomas without any apparent differences between individual cells in different groups ( Figure 1C, upper and middle panels) . Furthermore, we failed to detect apparent differences in the cellular differentiation pattern of tumors between the wild-type and Id2 À/À mice by immunohistochemical analysis for keratin 10 and keratin 14, which are markers for differentiating keratinocytes in the suprabasal region and proliferating keratinocytes in the basal layer, respectively (8, 14, 15) (Figure 1D , middle and lower panels). This held true for the expression of keratin 6, a marker for proliferating keratinocytes and hair follicles (8, 14, 15) (Figure 1D, upper panels) . These findings ruled out the possibility that the difference in tumor size was due to the histopathological origin or the differentiation status of the tumor cells. Taken together, these observations indicate that Id2 À/À mice are prone to developing skin tumors via chemical carcinogenesis and imply that Id2 is associated with the proliferation of tumor cells. In addition, there was no apparent difference in the TPA-induced hyperproliferation of the epidermis in tumor-free skin between the two groups ( Figure 1C , lower panels), suggesting that Id2 deficiency has no influence on the response of epidermal cells to long-term TPA treatment.
Significantly reduced number of epidermal cd T cells in Id2 À/À mice Although the reduced tumor size of Id2 À/À mice was consistent with the ability of Id2 to stimulate cell proliferation, the increased tumor frequency was opposed to it. Since epidermal cd T cells have been demonstrated to be an important host factor in protecting against skin tumor formation by two-step chemical carcinogenesis (8, 9) , we investigated whether epidermal cd T cells were present in the epidermal sheets of the ear auricles of Id2 À/À mice by whole mount immunohistochemistry. As shown in Figure 2A and B, the Id2 À/À mice exhibited a markedly reduced number of CD3 þ epidermal cd T cells (49.4 ± 51.7 cells/mm 2 ), which was similar to the findings for MHC class II þ Langerhans cells (44.6 ± 34.4 cells/mm 2 ) reported previously (16), whereas these cell types were easily identified in their wild-type littermates (cd T cells, 541.9 ± 112.5 cells/mm 2 ; Langerhans cells, 1202.6 ± 90.2 cells/mm 2 ). We further analyzed these cell populations by flow cytometry with antibodies against the T cell receptor Vc3 chain and MHC class II proteins. The percentages of epidermal cd T cells and Langerhans cells were 4.8 and 32% in the control wild-type mice, respectively, and 1.1 and 1.8% in the Id2 À/À mice, respectively ( Figure 2C ). These findings demonstrated that in addition to a deficiency of Langerhans cells, Id2 À/À mice are deficient in epidermal cd T cells and suggest that this deficiency underlies the tumor susceptibility of Id2 À/À mice.
Proliferation of tumor cells is reduced in Id2 À/À mice Next, we investigated the reason why the skin tumors of the Id2 À/À mice were smaller in size than those of the wild-type mice. Immunohistochemical analysis with an antibody against Ki-67 revealed that the percentages of Ki-67-positive tumor cells in the wild-type and Id2 À/À mice were 31.2 ± 4.5 and 16.5 ± 2.9%, respectively ( Figure 3A) , demonstrating a 1.9-fold reduction in the Id2 À/À mice. However, as shown in Figure 3B , the terminal deoxynucleotidyltransferase-mediated deoxyuridine triphosphate end-labeling assay indicated no difference in the percentages of apoptotic cells (0.67 ± 0.07% in wild-type tumor cells and 0.58 ± 0.10% in Id2 À/À tumor cells). In addition, the numbers of vessels within the tumors, as detected by the expression of von Willebrand factor, were not different between the wild-type and Id2 À/À mice, as shown in Figure 3C (7.7 ± 2.4 vessels per mm 2 in wildtype tumors and 6.2 ± 2.1 vessels per mm 2 in Id2 À/À tumors). These findings indicate that the reduced tumor size in Id2 À/À mice is due to the impaired proliferation of tumor cells and is not derived from increased apoptosis of tumors cells or a defect in blood supply within the tumors.
Reduced protein level of cyclin D1 in tumors in the Id2 À/À mice Regarding the expression of Id genes in the normal epidermis and skin tumors of wild-type mice, real-time reverse transcription-polymerase chain reaction indicated that the expression levels of Id1 and Id2 messenger RNA (mRNA) in skin tumors were 4.3 times and 3.0 times greater than those in the epidermis, respectively, and were similar to that of cyclin D1 mRNA (3.7 times), whereas that of Id3 was not altered ( Figure 4A ). To investigate the molecular events underlying the impaired cell proliferation of Id2 À/À skin tumor cells, we next Dual role for Id2 in chemical carcinogen-induced skin tumorigenesis compared the expression levels of the proteins related to cell cycle regulation by western blot analysis between Id2 À/À mice and their wild-type littermates. As shown in Figure 4B , no apparent difference was found for p16, p21, p27, cyclin E, CDK2 and CDK4, phosphorylated Erk 1/2, c-Fos or c-Myc. On the other hand, the expression level of cyclin D1 was reduced to 37.6% in the tumors of Id2 À/À mice compared with that in the wild-type tumors ( Figure 4B and C) . However, real-time polymerase chain reaction failed to detect a significant difference in the cyclin D1 mRNA level in tumors between the Id2 À/À mice and wild-type controls ( Figure 4D ). These results demonstrate that Id2 is required for maintaining an appropriate expression level of cyclin D1 protein, but not for its gene expression.
Discussion
We have revealed that Id2 plays two distinct roles in chemical carcinogen-induced tumorigenesis in mouse skin: one involves the establishment of an immunological skin barrier system against tumor formation, and the other involves the proliferation of developed tumor cells. The present study demonstrates the complex role of Id2 in skin tumorigenesis and corroborates the reports of the wide-ranging functions of Id2 in the control of biological processes.
Epidermal cd T cells play a pivotal role in tumor immunosurveillance in the skin, as clearly demonstrated by T cell receptor d chaindeficient mice that lack cd T cells (9) . This links the impaired epidermal cd T cell population in Id2 À/À mice with their susceptibility to skin tumor formation by chemical carcinogenesis. Intriguingly, mice deficient for Id1, another member of the Id gene family, are also deficient in epidermal Vc3 þ cd T cells and are susceptible to chemical carcinogen-induced skin tumors (8) . Although Id1 is critical for tumor angiogenesis, no impairment was detected in angiogenesis within tumors formed in Id1 À/À mice (8), which was similar to our findings for Id2 À/À mice. Instead, Vc3 þ T cells in the fetal thymi of Id1 À/À mice are unable to populate the epidermis due to their impaired expression of CXCR4 (8), a chemokine receptor that is crucial for the immigration of Vc3 þ T cells into the epidermis (16) . In Id2 À/À mice, we have also detected Vc3 þ T cells in the fetal thymi of embryonic day 18 mice at a frequency similar to that of their wild-type littermates, but we observed no alteration of CXCR4 expression in these cells (data not shown). Thus, functioning in a distinct manner, both Id1 and Id2 are required for the establishment of epidermal cd T cells.
The extent of the increased skin tumor formation in Id2 À/À mice is similar to that of mice lacking cd T cells (9) , implying that the susceptibility of Id2 À/À mice to two-step chemical tumorigenesis is mostly due to their lack of epidermal cd T cells. However, Id2 À/À mice also lacking in Langerhans cells (16) and natural killer cells (11) , and we cannot exclude the possibility of the contribution of these cells to the observed susceptibility of Id2 À/À mice. Langerhans cells are of particular interest because they are professional antigenpresenting cells in the epidermis and provide an immunological barrier by forming a dense cellular network (17, 18) . Although the precise role of Langerhans cells in the immune responses in the skin remains undetermined, it has been suggested that Langerhans cells are involved in the tumor immunosurveillance in the skin (17) . For example, depletion of Langerhans cells from the epidermis by the tumor promoter DMBA induced immunosuppression and promoted tumor development (19) . Recently, selective ablation of Langerhans cells in Langerin-diphthelia toxin receptor-enhanced green fluorescent protein knock-in mice clearly demonstrated that they played a critical role in the induction of the antitumor immune response after epidermal vaccination with a tumor antigen in a model system of ovalbumin-expressing melanoma cells (20) . The utilization of such A. Tokuriki et al. genetically engineered mice would provide direct evidence for the role of Langerhans cells in chemically induced skin tumorigenesis.
The impaired proliferation of Id2 À/À skin tumor cells is consistent with the ability of Id2 to simulate cell proliferation. However, we failed to detect a change in the expression of the cyclin-dependent kinase inhibitors that are thought to be major targets of Id proteins with regard to cell proliferation control. In addition, no apparent difference between the two groups was detected in the level of phosphorylated Erk 1/2, which reflects the activation of the Raf/Erk pathway by the DMBA-induced oncogenic H-ras gene (21) and by TPA via protein kinase C (22) . This also held true for c-Fos and c-Myc expression, which is enhanced by TPA through protein kinase C (22) .
How does Id2 participate in tumor cell proliferation? Among the molecules analyzed, cyclin D1 expression was reduced at the protein level in Id2 À/À tumors compared with that in the tumors of the wildtype mice. Furthermore, the expression level of cyclin D1 mRNA in tumors was similar in both genotypes. In accordance with this, reporter analysis with the mouse cyclin D1 promoter failed to detect an effect of Id2 on its reporter activity in a human keratinocyte cell line (data not shown). These observations suggest that Id2 is involved in regulating the protein level of cyclin D1. The pivotal role of cyclin D1 in chemical carcinogen-induced skin tumor formation has been demonstrated with cyclin D1-deificent mice (23) . Thus, our present work raises the interesting possibility that the regulation of the cyclin D1 protein level by Id2 underlies the proliferation of tumor cells in chemical carcinogen-induced skin tumors.
How Id2 is engaged in the regulation of the level of cyclin D1 protein is currently unknown. The level of cyclin D1 protein is regulated mainly by its degradation by the 26S proteasome (24) . Cyclin D1 that has been phosphorylated at the threonine 286 by glycogen synthase kinase 3b translocates from the nucleus to the cytoplasm (25, 26) and is ubiquitinated by the Skp-Cul1/Cdc53-F-box protein complex containing FBX4 or FBXW8 as an E3 ubiquitin ligase for proteasomal degradation (27, 28) . Other pathways to the degradation of cyclin D1 protein have also been demonstrated (24) . Id2 may regulate the gene expression of any of these factors that play a role in the degradation of cyclin D1 protein. Alternatively, Id2 may interact and regulate their functions at the protein level. In any case, although the factors mentioned above have a broad spectrum of target proteins (24) , the involvement of Id2 must be selective to cyclin D1 because the reduction at the protein level was confined to cyclin D1 among the factors examined in this study. Further investigation is required to clarify the molecular events that occur during the control of the degradation of cyclin D1 protein by Id2. Dual role for Id2 in chemical carcinogen-induced skin tumorigenesis
